Russian biomed firm ready to sell antibodies to Europe
23 Jul '15
PrimeBioMed, an innovative Russian company, is ready to start exporting to the West its new antibodies to diagnose tumors, reported RVC, Russia’s fund of funds for innovation.
This has been made possible after this RVC portfolio company completed earlier this summer its ISO 13485 international standard certification procedure. The audit was conducted by Germany’s BSI Group Deutschland GmbH. PrimeBioMed’s certificate is valid for three years.
The company’s plans for later this year and next year include the commercialization of its products internationally. PrimeBioMed is reported to be currently in talks over partnerships with medical centers in Italy and Switzerland.
PrimeBioMed has been in Russia’s biomed business for less than a year.